BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7942323)

  • 21. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings.
    Engelhardt G; Bögel R; Schnitzler C; Utzmann R
    Biochem Pharmacol; 1996 Jan; 51(1):29-38. PubMed ID: 8534265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings.
    Engelhardt G; Bögel R; Schnitzer C; Utzmann R
    Biochem Pharmacol; 1996 Jan; 51(1):21-8. PubMed ID: 8534264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
    Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
    Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absorption, bioavailability, and pharmacokinetics of tebufelone in the rat.
    Sietsema WK; Kelm GR; Deibel RM; Doyle MJ; Loomans ME; Smyth RE; Kinnett GO; Eichhold TH; Farmer RW
    J Pharm Sci; 1993 Jun; 82(6):610-2. PubMed ID: 8331535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
    Tornhamre S; Edenius C; Smedegård G; Sjöquist B; Lindgren JA
    Eur J Pharmacol; 1989 Oct; 169(2-3):225-34. PubMed ID: 2572437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
    Griswold DE; Marshall PJ; Webb EF; Godfrey R; Newton J; DiMartino MJ; Sarau HM; Gleason JG; Poste G; Hanna N
    Biochem Pharmacol; 1987 Oct; 36(20):3463-70. PubMed ID: 2823821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A useful method for differential evaluation of anti-inflammatory effects due to cyclooxygenase and 5-lipoxygenase inhibitions in mice.
    Ishii K; Motoyoshi S; Kawata J; Nakagawa H; Takeyama K
    Jpn J Pharmacol; 1994 Aug; 65(4):297-303. PubMed ID: 7990266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carborane-Based Tebufelone Analogs and Their Biological Evaluation In Vitro.
    Braun S; Paskaš S; Laube M; George S; Hofmann B; Lönnecke P; Steinhilber D; Pietzsch J; Mijatović S; Maksimović-Ivanić D; Hey-Hawkins E
    ChemMedChem; 2023 Jul; 18(14):e202300206. PubMed ID: 37160667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats.
    Lesch CA; Gilbertsen RB; Song Y; Dyer RD; Schrier D; Kraus ER; Sanchez B; Guglietta A
    J Pharmacol Exp Ther; 1998 Oct; 287(1):301-6. PubMed ID: 9765350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory effect of YPE-01, a novel diarylheptanoid derivative, on dermal inflammation in mice.
    Yamazaki R; Aiyama R; Matsuzaki T; Hashimoto S; Yokokura T
    Inflamm Res; 1998 Apr; 47(4):182-6. PubMed ID: 9628261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture.
    Bishop-Bailey D; Larkin SW; Warner TD; Chen G; Mitchell JA
    Br J Pharmacol; 1997 May; 121(1):125-33. PubMed ID: 9146896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catechol estrogens as inhibitors of leukotriene synthesis.
    Alanko J; Sievi E; Lähteenmäki T; Mucha I; Vapaatalo H; Parantainen J
    Biochem Pharmacol; 1998 Jan; 55(1):101-4. PubMed ID: 9413936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.
    Tries S; Neupert W; Laufer S
    Inflamm Res; 2002 Mar; 51(3):135-43. PubMed ID: 12005204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological properties of a new anti-inflammatory compound, alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolacto ne (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase.
    Hidaka T; Hosoe K; Ariki Y; Takeo K; Yamashita T; Katsumi I; Kondo H; Yamashita K; Watanabe K
    Jpn J Pharmacol; 1984 Sep; 36(1):77-85. PubMed ID: 6438380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avarol restores the altered prostaglandin and leukotriene metabolism in monocytes infected with human immunodeficiency virus type 1.
    Schröder HC; Bégin ME; Klöcking R; Matthes E; Sarma AS; Gasić M; Müller WE
    Virus Res; 1991 Nov; 21(3):213-23. PubMed ID: 1662847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2).
    Glaser KB; Carlson RP; Sung A; Bauer J; Lock YW; Holloway D; Sturm R; Hartman D; Walter T; Woeppel S
    Agents Actions; 1993; 39 Spec No():C30-2. PubMed ID: 8273577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs.
    Curnock AP; Robson PA; Yea CM; Moss D; Gadher S; Thomson TA; Westwood R; Ruuth E; Williamson RA
    J Pharmacol Exp Ther; 1997 Jul; 282(1):339-47. PubMed ID: 9223572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
    Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
    J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.